Condensed Consolidated Statement of Cash Flows  
(unaudited) Pfizer Inc and Subsidiary Companies

  Six Months Ended
(millions of dollars)
June 29, 1997

June 30, 1996
Operating Activities    
  • Net income
  • $1,059 $ 911
  • Adjustments to reconcile net income to net cash provided by operating activities:
  •    
  • Depreciation and amortization of intangibles
  • 244 207
  • Changes in operating assets and liabilities, net of effect of businesses acquired and divested
  • (642) (407)
  • Other
  • 16 12
    Net cash provided by operating activities 677 723
    Investing Activities    
  • Purchases of property, plant and equipment
  • (420) (313)
  • Purchases of short-term investments
  • (918) (1,716)
  • Proceeds from redemptions of short-term investments
  • 759 1,719
  • Acquisitions, net of cash acquired
  • (371)
  • Proceeds from sale of business
  • 353
  • Other investing activities
  • (1) 11
    Net cash used in investing activities (580) (317)
    Financing Activities    
  • Repayments of long-term debt
  • (269) (33)
  • Increase in short-term debt
  • 985 314
  • Purchases of common stock
  • (219)
  • Cash dividends paid
  • (440) (384)
  • Stock option transactions
  • 159 151
  • Other financing activities
  • 71 23
  • Net cash provided by financing activities
  • 287 71
  • Effect of exchange-rate changes on cash and cash equivalents
  • (20) (10)
  • Net increase in cash and cash equivalents
  • 364 467
  • Cash and cash equivalents at beginning of period
  • 1,150 403
  • Cash and cash equivalents at end of period
  • $1,514 $ 870

    Return to Mid Year Report Main Menu


    Logo Imagemap

    Copyright © 1996, 1997 Pfizer Inc All rights reserved.